Compare SLDP & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | TYRA |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.3M | 844.2M |
| IPO Year | N/A | 2021 |
| Metric | SLDP | TYRA |
|---|---|---|
| Price | $5.31 | $21.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $31.20 |
| AVG Volume (30 Days) | ★ 10.0M | 496.7K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,802,000.00 | N/A |
| Revenue This Year | $27.38 | N/A |
| Revenue Next Year | $36.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.85 | N/A |
| 52 Week Low | $0.68 | $6.42 |
| 52 Week High | $8.86 | $22.83 |
| Indicator | SLDP | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 68.26 |
| Support Level | $4.78 | $20.08 |
| Resistance Level | $5.33 | $22.83 |
| Average True Range (ATR) | 0.37 | 1.61 |
| MACD | -0.04 | 0.12 |
| Stochastic Oscillator | 42.77 | 84.28 |
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.